Replies to post #2663 on Biotech Values

[rstor1]

Thanks for the warning Dew.

It was an impulse buy - much less DD than appropriate. I looked at the dose-dependent results, I looked at the mode of admisistration, I looked at the tiny cap, and there did not seem to be a large downside vs the potential upside. It was worth a few thousand $.

Now I have to learn the company.

I've been doing this long enough that I should know the right way by now, but sometimes you go with your gut.

Regards,
Bob

[poorgradstudent]

is there a specific expertise that insbrooklad had?

[DewDiligence]

[OT]—Bill Fleckenstein’s short-only hedge fund fails to get off the ground:

http://finance.yahoo.com/news/short-sellers-u-stocks-agony-just-piles-121112330.html

People who followed Nastech (the Steven Quay company) several years ago may recall that Fleckenstein lost a lot of money on a long position in that stock.

[DewDiligence]

OPTN IPOs 8.63M* shares @$16—closes +19% on first day:

https://globenewswire.com/news-release/2017/10/13/1145257/0/en/Optinose-Announces-Pricing-of-Initial-Public-Offering.html

Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for ear, nose and throat (ENT) or allergy specialists. The Company’s first two products rely on patented Exhalation Delivery Systems (EDS), which is capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products with the potential for meaningful new clinical benefits. Optinose developed its first product, Onzetra Xsail (sumatriptan nasal powder), through the completion of phase 3 and subsequently out-licensed the product to Ostuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis.

…The Company is also currently engaged in the early development of products for neurologic orphan diseases where the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (Prader-Willi Syndrome, Autism, others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway.

The bold-face text is reminiscent of a notable biotech failure discussed here in years gone by. I probably don’t need to name names.

*Assuming exercise of underwriter’s option.

[DewDiligence]

Dr. Steven Quay* weighs in on COVID-19 treatment:

https://www.globenewswire.com/news-release/2020/03/30/2008285/0/en/New-COVID-19-HOPE-Clinical-Trial-Recommendations-Introduced-Today-May-Reduce-or-Eliminate-Mechanical-Ventilation-for-Coronavirus-Patients.html

Physician-scientist and inventor Dr. Steven Quay, MD, PhD, is announcing a new combination treatment with the potential to improve pulmonary function and reduce or eliminate mechanical ventilation in patients with the coronavirus infection. The treatment uses two drugs previously approved by the FDA for other conditions: nebulized (inhaled as a fine mist) heparin combined with N-acetylcysteine (NAC), termed “H-NAC." Dr. Quay is making this new clinical trial protocol (called the COVID-19 HOPE Trial) available for use by the worldwide medical community. Starting today, doctors around the world are invited to directly download the protocol free of charge at www.DrQuay.com .

He doesn’t even have a company anymore, LOL.

*Former CEO of Nastech (NSTK) and various other failed biotech companies.